These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 32861197)

  • 21. Gut microbiome dysbiosis in Alzheimer's disease and mild cognitive impairment: A systematic review and meta-analysis.
    Jemimah S; Chabib CMM; Hadjileontiadis L; AlShehhi A
    PLoS One; 2023; 18(5):e0285346. PubMed ID: 37224131
    [TBL] [Abstract][Full Text] [Related]  

  • 22. APOEɛ4-TOMM40L Haplotype Increases the Risk of Mild Cognitive Impairment Conversion to Alzheimer's Disease.
    Cardoso R; Lemos C; Oliveiros B; Almeida MR; Baldeiras I; Pereira CF; Santos A; Duro D; Vieira D; Santana I; Oliveira CR
    J Alzheimers Dis; 2020; 78(2):587-601. PubMed ID: 33016906
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Don't forget about tau: the effects of ApoE4 genotype on Alzheimer's disease cerebrospinal fluid biomarkers in subjects with mild cognitive impairment-data from the Dementia Competence Network.
    Benson GS; Bauer C; Hausner L; Couturier S; Lewczuk P; Peters O; Hüll M; Jahn H; Jessen F; Pantel J; Teipel SJ; Wagner M; Schuchhardt J; Wiltfang J; Kornhuber J; Frölich L
    J Neural Transm (Vienna); 2022 Jun; 129(5-6):477-486. PubMed ID: 35061102
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Population-Level Configurations of Gut Mycobiome Across 6 Ethnicities in Urban and Rural China.
    Sun Y; Zuo T; Cheung CP; Gu W; Wan Y; Zhang F; Chen N; Zhan H; Yeoh YK; Niu J; Du Y; Zhang F; Wen Y; Yu J; Sung JJY; Chan PKS; Chan FKL; Wang K; Ng SC; Miao Y
    Gastroenterology; 2021 Jan; 160(1):272-286.e11. PubMed ID: 32956679
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study.
    Ten Kate M; Redolfi A; Peira E; Bos I; Vos SJ; Vandenberghe R; Gabel S; Schaeverbeke J; Scheltens P; Blin O; Richardson JC; Bordet R; Wallin A; Eckerstrom C; Molinuevo JL; Engelborghs S; Van Broeckhoven C; Martinez-Lage P; Popp J; Tsolaki M; Verhey FRJ; Baird AL; Legido-Quigley C; Bertram L; Dobricic V; Zetterberg H; Lovestone S; Streffer J; Bianchetti S; Novak GP; Revillard J; Gordon MF; Xie Z; Wottschel V; Frisoni G; Visser PJ; Barkhof F
    Alzheimers Res Ther; 2018 Sep; 10(1):100. PubMed ID: 30261928
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alterations in the gut mycobiome with coronary artery disease severity.
    An K; Jia Y; Xie B; Gao J; Chen Y; Yuan W; Zhong J; Su P; Liu X
    EBioMedicine; 2024 May; 103():105137. PubMed ID: 38703606
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cognitive Function Associated with Gut Microbial Abundance in Sucrose and S-Adenosyl-L-Methionine (SAMe) Metabolic Pathways.
    Jeong S; Huang LK; Tsai MJ; Liao YT; Lin YS; Hu CJ; Hsu YH
    J Alzheimers Dis; 2022; 87(3):1115-1130. PubMed ID: 35431236
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cerebrospinal fluid levels of YKL-40 in prodromal Alzheimer's disease.
    Wang L; Gao T; Cai T; Li K; Zheng P; Liu J;
    Neurosci Lett; 2020 Jan; 715():134658. PubMed ID: 31794792
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasma apolipoprotein E levels in longitudinally followed patients with mild cognitive impairment and Alzheimer's disease.
    Giannisis A; Al-Grety A; Carlsson H; Patra K; Twohig D; Sando SB; Lauridsen C; Berge G; Grøntvedt GR; Bråthen G; White LR; Kultima K; Nielsen HM
    Alzheimers Res Ther; 2022 Aug; 14(1):115. PubMed ID: 36002891
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cognitive impairment in late-life bipolar disorder is not associated with Alzheimer's disease pathological signature in the cerebrospinal fluid.
    Forlenza OV; Aprahamian I; Radanovic M; Talib LL; Camargo MZ; Stella F; Machado-Vieira R; Gattaz WF
    Bipolar Disord; 2016 Feb; 18(1):63-70. PubMed ID: 26876913
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exploration of acupuncture therapy in the treatment of MCI patients with the ApoE ε4 gene based on the brain-gut axis theory.
    Jin Y; Chen J; Chai Q; Zhu J; Jin X
    BMC Complement Med Ther; 2023 Jul; 23(1):227. PubMed ID: 37422636
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Altered microbiomes distinguish Alzheimer's disease from amnestic mild cognitive impairment and health in a Chinese cohort.
    Liu P; Wu L; Peng G; Han Y; Tang R; Ge J; Zhang L; Jia L; Yue S; Zhou K; Li L; Luo B; Wang B
    Brain Behav Immun; 2019 Aug; 80():633-643. PubMed ID: 31063846
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neuropsychiatric symptoms differently affect mild cognitive impairment and Alzheimer's disease patients: a retrospective observational study.
    Scaricamazza E; Colonna I; Sancesario GM; Assogna F; Orfei MD; Franchini F; Sancesario G; Mercuri NB; Liguori C
    Neurol Sci; 2019 Jul; 40(7):1377-1382. PubMed ID: 30903419
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Amyloid cascade and tau pathology cerebrospinal fluid markers in mild cognitive impairment with regards to Alzheimer's disease cerebral metabolic signature.
    Alexopoulos P; Guo LH; Jiang M; Bujo H; Grimmer T; Förster S; Drzezga A; Kurz A; Perneczky R
    J Alzheimers Dis; 2013; 36(2):401-8. PubMed ID: 23609762
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interaction between personality traits and cerebrospinal fluid biomarkers of Alzheimer's disease pathology modulates cognitive performance.
    Tautvydaitė D; Kukreja D; Antonietti JP; Henry H; von Gunten A; Popp J
    Alzheimers Res Ther; 2017 Feb; 9(1):6. PubMed ID: 28153054
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ketogenic diet rescues cognition in ApoE4+ patient with mild Alzheimer's disease: A case study.
    Morrill SJ; Gibas KJ
    Diabetes Metab Syndr; 2019; 13(2):1187-1191. PubMed ID: 31336463
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multielectrode array analysis of cerebrospinal fluid in Alzheimer's disease versus mild cognitive impairment: a potential diagnostic and treatment biomarker.
    Görtz P; Siebler M; Ihl R; Henning U; Luckhaus C; Supprian T; Lange-Asschenfeldt C
    Biochem Biophys Res Commun; 2013 May; 434(2):293-7. PubMed ID: 23541573
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The gut mycobiome of the Human Microbiome Project healthy cohort.
    Nash AK; Auchtung TA; Wong MC; Smith DP; Gesell JR; Ross MC; Stewart CJ; Metcalf GA; Muzny DM; Gibbs RA; Ajami NJ; Petrosino JF
    Microbiome; 2017 Nov; 5(1):153. PubMed ID: 29178920
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic Value of Gut Microbiome for Conversion from Mild Cognitive Impairment to Alzheimer's Disease Dementia within 4 Years: Results from the AlzBiom Study.
    Laske C; Müller S; Munk MHJ; Honold I; Willmann M; Peter S; Schoppmeier U
    Int J Mol Sci; 2024 Feb; 25(3):. PubMed ID: 38339197
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genome-wide significant risk factors for Alzheimer's disease: role in progression to dementia due to Alzheimer's disease among subjects with mild cognitive impairment.
    Lacour A; Espinosa A; Louwersheimer E; Heilmann S; Hernández I; Wolfsgruber S; Fernández V; Wagner H; Rosende-Roca M; Mauleón A; Moreno-Grau S; Vargas L; Pijnenburg YA; Koene T; Rodríguez-Gómez O; Ortega G; Ruiz S; Holstege H; Sotolongo-Grau O; Kornhuber J; Peters O; Frölich L; Hüll M; Rüther E; Wiltfang J; Scherer M; Riedel-Heller S; Alegret M; Nöthen MM; Scheltens P; Wagner M; Tárraga L; Jessen F; Boada M; Maier W; van der Flier WM; Becker T; Ramirez A; Ruiz A
    Mol Psychiatry; 2017 Jan; 22(1):153-160. PubMed ID: 26976043
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.